Recurrent clostridium difficile infection: From colonization to cure

Anaerobe

Volumn 34, Issue , 2015, Pages 59-73

  Shields, Kelsey ^a   Araujo Castillo, Roger V ^a   Theethira, Thimmaiah G ^a   Alonso, Carolyn D ^a   Kelly, Ciaran P ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Antibiotic; Fecal microbiota therapy; Infection control; Infectious diarrhea; Nosocomial infection; Toxin

Indexed keywords

ACTOXUMAB; BEZLOTOXUMAB; CADAZOLID; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; COLESTIPOL; COLESTYRAMINE; FIDAXOMICIN; IMMUNOGLOBULIN; LFF 571; METRONIDAZOLE; NITAZOXANIDE; PLACEBO; PROBIOTIC AGENT; RAMOPLANIN; RECOMBINANT VACCINE; RIFAXIMIN; SUROTOMYCIN; TEICOPLANIN; TIGECYCLINE; TOLEVAMER; VANCOMYCIN;

ADAPTIVE IMMUNITY; BACTERIAL COLONIZATION; BACTERIAL VIRULENCE; BIOLOGICAL THERAPY; CLINICAL FEATURE; CLOSTRIDIUM DIFFICILE INFECTION; DRUG EFFICACY; ENVIRONMENTAL FACTOR; FECAL MICROBIOTA TRANSPLANT; FECES MICROFLORA; HUMAN; IMMUNOTHERAPY; INFECTION RISK; INNATE IMMUNITY; LOADING DRUG DOSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RECURRENT INFECTION; REVIEW; RISK ASSESSMENT; CLOSTRIDIUM INFECTIONS; HETEROZYGOTE; INCIDENCE; ISOLATION AND PURIFICATION; MICROBIOLOGY; PATHOLOGY; PEPTOCLOSTRIDIUM DIFFICILE; RECURRENT DISEASE; RISK FACTOR;

CLOSTRIDIUM DIFFICILE;

CARRIER STATE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; HUMANS; INCIDENCE; RECURRENCE; RISK FACTORS;

EID: 84929658134     PISSN: 10759964     EISSN: 10958274     Source Type: Journal    
DOI: 10.1016/j.anaerobe.2015.04.012     Document Type: Review

References (222)

1. Hall I.C., O'Toole E. Intestinal flora in new-born infants: with a description of a new pathogenic anaerobe, Bacillus difficilis. Am. J. Dis. Child. 1935, 49(2):390-402.
2. Bartlett J.G., Gerding D.N. Clinical recognition and diagnosis of Clostridium difficile infection. Clin. Infect. Dis. 2008, 46(Suppl.1):S12-S18.
3. Dubberke E.R., Olsen M.A. Burden of Clostridium difficile on the healthcare system. Clin. Infect. Dis. 2012, 55(Suppl.2):S88-S92.
4. Kyne L., Hamel M.B., Polavaram R., et al. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin. Infect. Dis. 2002, 34(3):346-353.
5. Lucado J., Gould C., Elixhauser A. Clostridium difficile infections (CDI) in Hospital Stays, 2009 April 30, 2014, Available from:. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb124.pdf.
6. Peery A.F., Dellon E.S., Lund J., et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology 2012, 143(5):1179-1187. e3.
7. Aslam S., Hamill R.J., Musher D.M. Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect. Dis. 2005, 5(9):549-557.
8. Bauer M.P., Notermans D.W., Van Benthem B.H., et al. Clostridium difficile infection in Europe: a hospital-based survey. Lancet 2011, 377(9759):63-73.
9. Dubberke E.R., Butler A.M., Yokoe D.S., et al. Amulticenter study of Clostridium difficile infection rates from 2000-2006. Infect. Control Hosp. Epidemiol. 2010, 31(10):1030.
10. VerLee K.E., Finks J.L., Wilkins M.J., et al. Michigan Clostridium difficile hospital discharges: frequency, mortality, and charges, 2002-2008. Public Health Rep. 2012, 127(1):62.
11. Campbell R.J., Giljahn L., Machesky K., et al. Clostridium difficile infection in Ohio hospitals and nursing homes during 2006. Infect. Control Hosp. Epidemiol. 2009, 30(6):526-533.
12. Lessa F.C., Mu Y., Bamberg W.M., et al. Burden of Clostridium difficile infection in the United States. N.Engl. J. Med. 2015, 372(9):825-834.
13. Centers for Disease Control and Prevention (CDC) Vital signs: preventing Clostridium difficile infections. Morb. Mortal. Wkly. Rep. 2012, 61(9):157.
14. Ricciardi R., Rothenberger D.A., Madoff R.D., et al. Increasing prevalence and severity of Clostridium difficile colitis in hospitalized patients in the United States. Arch. Surg. 2007, 142(7):624-631.
15. Rupnik M., Wilcox M.H., Gerding D.N. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat. Rev. Microbiol. 2009, 7(7):526-536.
16. Garey K., Sethi S., Yadav Y., et al. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J.Hosp. Infect. 2008, 70(4):298-304.
17. Johnson S. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. J.Infect. 2009, 58(6):403-410.
18. Kelly C. Can we identify patients at high risk of recurrent Clostridium difficile infection?. Clin. Microbiol. Infect. 2012, 18(s6):21-27.
19. McFarland L.V., Surawicz C.M., Greenberg R.N., et al. Arandomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. J.Am. Med. Assoc. 1994, 271(24):1913-1918.
20. McFarland L.V., Surawicz C.M., Rubin M., et al. Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect. Control Hosp. Epidemiol. 1999, 20(1):43-50.
21. Ghantoji S., Sail K., Lairson D., et al. Economic healthcare costs of Clostridium difficile infection: a systematic review. J.Hosp. Infect. 2010, 74(4):309-318.
22. McFarland L.V., Elmer G.W., Surawicz C.M. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am. J. Gastroenterol. 2002, 97(7):1769-1775.
23. Taylor N., Thorne G., Bartlett J. Comparison of two toxins produced by Clostridium difficile. Infect. Immun. 1981, 34(3):1036-1043.
24. Genth H., Dreger S.C., Huelsenbeck J., et al. Clostridium difficile toxins: more than mere inhibitors of Rho proteins. Int. J. Biochem. Cell Biol. 2008, 40(4):592-597.
25. Savidge T.C., Pan W.-H., Newman P., et al. Clostridium difficile toxin B is an inflammatory enterotoxin in human intestine. Gastroenterology 2003, 125(2):413-420.
26. Sun X., He X., Tzipori S., et al. Essential role of the glucosyltransferase activity in Clostridium difficile toxin-induced secretion of TNF-α by macrophages. Microb. Pathog. 2009, 46(6):298-305.
27. Bartlett J.G., Chang T.W., Gurwith M., et al. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N.Engl. J. Med. 1978, 298(10):531-534.
28. Cohen S.H., Gerding D.N., Johnson S., et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect. Control Hosp. Epidemiol. 2010, 31(5):431-455.
29. Gerding D.N., Johnson S., Peterson L.R., et al. Clostridium difficile-associated diarrhea and colitis. Infect. Control Hosp. Epidemiol. 1995, 16(8):459-477.
30. Kelly C.P., LaMont J.T. Clostridium difficile-more difficult than ever. N.Engl. J. Med. 2008, 359(18):1932-1940.
31. Warny M., Pepin J., Fang A., et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005, 366(9491):1079-1084.
32. Carter G.P., Rood J.I., Lyras D. The role of toxin A and toxin B in the virulence of Clostridium difficile. Trends Microbiol. 2011, 20(1):21-29.
33. Loo V.G., Poirier L., Miller M.A., et al. Apredominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N.Engl. J. Med. 2005, 353(23):2442-2449.
34. Pépin J., Valiquette L., Alary M.-E., et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. Can. Med. Assoc. J. 2004, 171(5):466-472.
35. Pépin J., Alary M.-E., Valiquette L., et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin. Infect. Dis. 2005, 40(11):1591-1597.
36. Pépin J., Routhier S., Gagnon S., et al. Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. Clin. Infect. Dis. 2006, 42(6):758-764.
37. Holbourn K.P., Shone C.C., Acharya K. Afamily of killer toxins. FEBS J. 2006, 273(20):4579-4593.
38. Perelle S., Gibert M., Bourlioux P., et al. Production of a complete binary toxin (actin-specific ADP-ribosyltransferase) by Clostridium difficile CD196. Infect. Immun. 1997, 65(4):1402-1407.
39. McDonald L.C., Killgore G.E., Thompson A., et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N.Engl. J. Med. 2005, 353(23):2433-2441.
40. Stewart D.B., Berg A., Hegarty J. Predicting recurrence of C.difficile colitis using bacterial virulence factors: binary toxin is the key. J.Gastrointest. Surg. 2013, 17(1):118-125.
41. Stewart D.B., Berg A.S., Hegarty J.P. Single nucleotide polymorphisms of the tcdC gene and presence of the binary toxin gene predict recurrent episodes of Clostridium difficile infection. Ann. Surg. 2014 Aug, 260(2):299-304.
42. Fekety R., Kim K.-H., Brown D., et al. Epidemiology of antibiotic-associated colitis: isolation of Clostridium difficile from the hospital environment. Am. J. Med. 1981, 70(4):906-908.
43. Gerding D.N., Muto C.A., Owens R.C. Measures to control and prevent Clostridium difficile infection. Clin. Infect. Dis. 2008, 46(Suppl.1):S43-S49.
44. McFarland L.V., Mulligan M.E., Kwok R.Y., et al. Nosocomial acquisition of Clostridium difficile infection. N.Engl. J. Med. 1989, 320(4):204-210.
45. Cartmill T., Shrimpton S., Panigrahi H., et al. Nosocomial diarrhoea due to a single strain of Clostridium difficile: a prolonged outbreak in elderly patients. Age Ageing 1992, 21(4):245-249.
46. Moshkowitz M., Ben-Baruch E., Kline Z., et al. Risk factors for severity and relapse of pseudomembranous colitis in an elderly population. Colorectal Dis. 2007, 9(2):173-177.
47. Zilberberg M.D., Reske K., Olsen M., et al. Development and validation of a recurrent Clostridium difficile risk-prediction model. J.Hosp. Med. 2014 Jul, 9(7):418-423.
48. Gupta A., Khanna S. Community-acquired Clostridium difficile infection: an increasing public health threat. Infect. Drug Resist. 2014, 7:63.
49. Khanna S., Pardi D.S., Aronson S.L., et al. The epidemiology of community-acquired Clostridium difficile infection: a population-based study. Am. J. Gastroenterol. 2011, 107(1):89-95.
50. Khanna S., Pardi D.S., Aronson S.L., et al. The epidemiology of community-acquired Clostridium difficile infection: a population-based study. Am. J. Gastroenterol. 2012, 107(1):89-95.
51. Collins C.E., Ayturk M.D., Flahive J.M., et al. Epidemiology and outcomes of community-acquired Clostridium difficile infections in medicare beneficiaries. J.Am. Coll. Surg. 2014, 218(6):1141-1147. e1.
52. Do A.N., Fridkin S.K., Yechouron A., et al. Risk factors for early recurrent Clostridium difficile-associated diarrhea. Clin. Infect. Dis. 1998, 26(4):954-959.
53. Khanna S., Pardi D.S., Aronson S.L., et al. Outcomes in community-acquired Clostridium difficile infection. Aliment. Pharmacol. Ther. 2012, 35(5):613-618.
54. Barbut F., Richard A., Hamadi K., et al. Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea. J.Clin. Microbiol. 2000, 38(6):2386-2388.
55. Jabbar U., Leischner J., Kasper D., et al. Effectiveness of alcohol-based hand rubs for removal of Clostridium difficile spores from hands. Infect. Control Hosp. Epidemiol. 2010, 31(6):565-570.
56. Moore P., Kyne L., Martin A., et al. Germination efficiency of clinical Clostridium difficile spores and correlation with ribotype, disease severity and therapy failure. J.Med. Microbiol. 2013, 62(Pt 9):1405-1413.
57. Oka K., Osaki T., Hanawa T., et al. Molecular and microbiological characterization of Clostridium difficile isolates from single, relapse, and reinfection cases. J.Clin. Microbiol. 2012, 50(3):915-921.
58. Centers for Disease Control and Prevention (CDC) Severe Clostridium difficile-associated disease in populations previously at low risk-four states, 2005. Morb. Mortal. Wkly. Rep. 2005, 54(47):1201.
59. Young V.B., Schmidt T.M. Antibiotic-associated diarrhea accompanied by large-scale alterations in the composition of the fecal microbiota. J.Clin. Microbiol. 2004, 42(3):1203-1206.
60. Chang J.Y., Antonopoulos D.A., Kalra A., et al. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. J.Infect. Dis. 2008, 197(3):435-438.
61. Nair S., Yadav D., Corpuz M., et al. Clostridium difficile colitis: factors influencing treatment failure and relapse-a prospective evaluation. Am. J. Gastroenterol. 1998, 93(10):1873-1876.
62. Berg R.D. The indigenous gastrointestinal microflora. Trends Microbiol. 1996, 4(11):430-435.
63. Vollaard E., Clasener H. Colonization resistance. Antimicrob. Agents Chemother. 1994, 38(3):409.
64. Khoruts A., Dicksved J., Jansson J.K., et al. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. J.Clin. Gastroenterol. 2010, 44(5):354-360.
65. Wilson K.H. The microecology of Clostridium difficile. Clin. Infect. Dis. 1993, 16(Suppl.4):S214-S218.
66. Kelly C.P. Current strategies for management of initial Clostridium difficile infection. J.Hosp. Med. 2012, 7(S3):S5-S10.
67. Dial S., Kezouh A., Dascal A., et al. Patterns of antibiotic use and risk of hospital admission because of Clostridium difficile infection. Can. Med. Assoc. J. 2008, 179(8):767-772.
68. Muto C.A., Pokrywka M., Shutt K., et al. Alarge outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect. Control Hosp. Epidemiol. 2005, 26(3):273-280.
69. Pépin J., Saheb N., Coulombe M.-A., et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin. Infect. Dis. 2005, 41(9):1254-1260.
70. Slimings C., Riley T.V. Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J.Antimicrob. Chemother. 2013, dkt477.
71. D'Agostino R.B., Collins S.H., Pencina K.M., et al. Risk estimation for recurrent Clostridium difficile infection based on clinical factors. Clin. Infect. Dis. 2014, 58(10):1386-1393.
72. Fekety R., McFarland L.V., Surawicz C.M., et al. Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin. Infect. Dis. 1997, 24(3):324-333.
73. Hu M.Y., Katchar K., Kyne L., et al. Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection. Gastroenterology 2009, 136(4):1206-1214.
74. Venugopal A.A., Szpunar S., Sanchez K., et al. Assessment of 30-day all-cause mortality in metronidazole-treated patients with Clostridium difficile infection. Scand. J. Infect. Dis. 2013, 45(10):786-790.
75. Kelly C.P., Kyne L. The host immune response to Clostridium difficile. J.Med. Microbiol. 2011, 60(8):1070-1079.
76. Louie T.J., Miller M.A., Crook D.W., et al. Effect of age on treatment outcomes in Clostridium difficile infection. J.Am. Geriatr. Soc. 2013, 61(2):222-230.
77. Kyne L., Sougioultzis S., McFarland L.V., et al. Underlying disease severity as a major risk factor for nosocomial Clostridium difficile diarrhea. Infect. Control Hosp. Epidemiol. 2002, 23(11):653-659.
78. Vesta K.S., Wells P.G., Gentry C.A., et al. Specific risk factors for Clostridium difficile-associated diarrhea: a prospective, multicenter, case control evaluation. Am. J. Infect. Control 2005, 33(8):469-472.
79. Horn S.D., Sharkey P.D., Bertram D.A. Measuring severity of illness: homogeneous case mix groups. Med. Care 1983, 14-30.
80. Arora V., Kachroo S., Ghantoji S.S., et al. High Horn's index score predicts poor outcomes in patients with Clostridium difficile infection. J.Hosp. Infect. 2011, 79(1):23-26.
81. Kyne L., Warny M., Qamar A., et al. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001, 357(9251):189-193.
82. Henrich T.J., Krakower D., Bitton A., et al. Clinical risk factors for severe Clostridium difficile-associated disease. Emerg. Infect. Dis. 2009, 15(3):415.
83. Rodríguez-Pardo D., Almirante B., Bartolomé R.M., et al. Epidemiology of Clostridium difficile infection and risk factors for unfavorable clinical outcomes: results of a hospital-based study in Barcelona, Spain. J.Clin. Microbiol. 2013, 51(5):1465-1473.
84. Redelings M.D., Sorvillo F., Mascola L. Increase in Clostridium difficile-related mortality rates, United States, 1999-2004. Emerg. Infect. Dis. 2007, 13(9):1417.
85. Warny M., Vaerman J.-P., Avesani V., et al. Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection. Infect. Immun. 1994, 62(2):384-389.
86. Hippenstiel S., Soeth S., Kellas B., et al. Rho proteins and the p38-MAPK pathway are important mediators for LPS-induced interleukin-8 expression in human endothelial cells. Blood 2000, 95(10):3044-3051.
87. Warny M., Keates A.C., Keates S., et al. p38 MAP kinase activation by Clostridium difficile toxin A mediates monocyte necrosis, IL-8 production, and enteritis. J.Clin. Invest. 2000, 105(8):1147-1156.
88. El Feghaly R.E., Stauber J.L., Deych E., et al. Markers of intestinal inflammation, not bacterial burden, correlate with clinical outcomes in Clostridium difficile infection. Clin. Infect. Dis. 2013, 56(12):1713-1721.
89. Yacyshyn M.B., Yacyshyn B. Editorial commentary: the role of gut inflammation in recurrent Clostridium difficile - associated disease. Clin. Infect. Dis. 2013, 56(12):1722-1723.
90. Boone J., Archbald-Pannone L., Wickham K., et al. Ribotype 027 Clostridium difficile infections with measurable stool toxin have increased lactoferrin and are associated with a higher mortality. Eur. J. Clin. Microbiol. Infect. Dis. 2014, 33(6):1045-1051.
91. Jiang Z.-D., Okhuysen P.C., Guo D.-C., et al. Genetic susceptibility to enteroaggregative Escherichia coli diarrhea: polymorphism in the interleukin-8 promotor region. J.Infect. Dis. 2003, 188(4):506-511.
92. Jiang Z.D., Garey K.W., Price M., et al. Association of Interleukin-8 polymorphism and immunoglobulin G anti-toxin A in patients with Clostridium difficile-associated diarrhea. Clin. Gastroenterol. Hepatol. 2007, 5(8):964-968.
93. Garey K.W., Jiang Z.-D., Ghantoji S., et al. Acommon polymorphism in the interleukin-8 gene promoter is associated with an increased risk for recurrent Clostridium difficile infection. Clin. Infect. Dis. 2010, 51(12):1406-1410.
94. Kim H., Kokkotou E., Na X., et al. Clostridium difficile toxin A-induced colonocyte apoptosis involves p53-dependent p21 (WAF1/CIP1) induction via p38 mitogen-activated protein kinase. Gastroenterology 2005, 129(6):1875-1888.
95. Collini P.J., Bauer M., Kuijper E., et al. Clostridium difficile infection in HIV-seropositive individuals and transplant recipients. J.Infect. 2012, 64(2):131-147.
96. Kelly C.R., Ihunnah C., Fischer M., et al. Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am. J. Gastroenterol. 2014, 109(7):1065-1071.
97. Hashash J.G., Binion D.G. Managing Clostridium difficile in inflammatory bowel disease (IBD). Curr. Gastroenterol. Rep. 2014, 16(7):1-6.
98. Nitzan O., Elias M., Chazan B., et al. Clostridium difficile and inflammatory bowel disease: role in pathogenesis and implications in treatment. World J. Gastroenterol. 2013, 19(43):7577.
99. Issa M., Vijayapal A., Graham M.B., et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 2007, 5(3):345-351.
100. Kelsen J.R., Kim J., Latta D., et al. Recurrence rate of Clostridium difficile infection in hospitalized pediatric patients with inflammatory bowel disease. Inflamm. Bowel Dis. 2011, 17(1):50-55.
101. Libot A., Issa M., Zadvornova Y., et al. Initial vancomycin monotherapy is associated with higher rates of subsequent Clostridium difficile infection in inflammatory bowel disease population. Gastroenterology 2011, 140(5):S-159.
102. Debast S., Bauer M., Kuijper E. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin. Microbiol. Infect. 2014, 20(s2):1-26.
103. Surawicz C.M., Brandt L.J., Binion D.G., et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am. J. Gastroenterol. 2013, 108(4):478-498.
104. Eyre D.W., Walker A.S., Wyllie D., et al. Predictors of first recurrence of Clostridium difficile infection: implications for initial management. Clin. Infect. Dis. 2012, 55(Suppl.2):S77-S87.
105. Hebert C., Du H., Peterson L.R., et al. Electronic health record-based detection of risk factors for Clostridium difficile infection relapse. Infect. Control Hosp. Epidemiol. 2013, 34(4):407-414.
106. Marsh J.W., Curry S.R. Therapeutic approaches for Clostridium difficile infections. Curr. Protoc. Microbiol. 2012, 9A. 3.1-9A. 3.9.
107. Edwards D.I., Thompson E.J., Tomusange J., et al. Inactivation of metronidazole by aerobic organisms. J.Antimicrob. Chemother. 1979 May, 5(3):315-316. 5(3):315-6(3):315-6.
108. Drekonja D.M., Butler M., MacDonald R., et al. Comparative effectiveness of Clostridium difficile treatments - a systematic review. Ann. Intern. Med. 2011, 155(12):839-847.
109. O'Horo J., Jindai K., Kunzer B., et al. Treatment of recurrent Clostridium difficile infection: a systematic review. Infection 2014, 42(1):43-59.
110. Nelson R.L., Kelsey P., Leeman H., et al. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst. Rev. 2011, 9.
111. Tedesco F.J., Gordon D., Fortson W.C. Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis. Am. J. Gastroenterol. 1985, 80(11):867-868.
112. Buggy B.P., Fekety R., Silva J. Therapy of relapsing Clostridium difficile associated diarrhea and colitis with the combination of vancomycin and rifampin. J.Clin. Gastroenterol. 1987, 9(2):155-159.
113. Johnson S., Louie T.J., Gerding D.N., et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin. Infect. Dis. 2014 Aug, 59(3):345-354. ciu313.
114. Zar F.A., Bakkanagari S.R., Moorthi K., et al. Acomparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin. Infect. Dis. 2007, 45(3):302-307.
115. Bishara J., Wattad M., Paul M. Vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea. Clin. Infect. Dis. 2007, 45(12):1646-1647.
116. Venugopal A.A., Johnson S. Fidaxomicin: a novel macrocyclic antibiotic approved for treatment of Clostridium difficile infection. Clin. Infect. Dis. 2012, 54(4):568-574.
117. Babakhani F., Bouillaut L., Sears P., et al. Fidaxomicin inhibits toxin production in Clostridium difficile. J.Antimicrob. Chemother. 2013, 68(3):515-522.
118. Credito K.L., Appelbaum P.C. Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species. Antimicrob. Agents Chemother. 2004, 48(11):4430-4434.
119. Louie T.J., Miller M.A., Mullane K.M., et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N.Engl. J. Med. 2011, 364(5):422-431.
120. Cornely O.A., Crook D.W., Esposito R., et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect. Dis. 2012, 12(4):281-289.
121. Louie T.J., Cannon K., Byrne B., et al. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clin. Infect. Dis. 2012, 55(Suppl.2):S132-S142.
122. Hecht D.W., Galang M.A., Sambol S.P., et al. Invitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob. Agents Chemother. 2007, 51(8):2716-2719.
123. Johnson S., Schriever C., Galang M., et al. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin. Infect. Dis. 2007, 44(6):846-848.
124. Johnson S., Schriever C., Patel U., et al. Rifaximin redux: treatment of recurrent Clostridium difficile infections with Rifaximin immediately post-vancomycin treatment. Anaerobe 2009, 15(6):290-291.
125. Garey K.W., Ghantoji S.S., Shah D.N., et al. Arandomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J.Antimicrob. Chemother. 2011, 66(12):2850-2855.
126. Mattila E., Arkkila P., Mattila P., et al. Rifaximin in the treatment of recurrent Clostridium difficile infection. Aliment. Pharmacol. Ther. 2013, 37(1):122-128.
127. Marchese A., Salerno A., Pesce A., et al. Invitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species. Chemotherapy 1999, 46(4):253-266.
128. Carman R.J., Boone J.H., Grover H., et al. Invivo selection of rifamycin-resistant Clostridium difficile during rifaximin therapy. Antimicrob. Agents Chemother. 2012, 56(11):6019-6020.
129. Johnson S., Gerding D.N. Fidaxomicin "chaser" regimen following vancomycin for patients with multiple Clostridium difficile recurrences. Clin. Infect. Dis. 2013, 56(2):309-310.
130. Kelly C.P. Fecal microbiota transplantation - an old therapy comes of age. N.Engl. J. Med. 2013, 368(5):474-475.
131. van Nood E., Vrieze A., Nieuwdorp M., et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N.Engl. J. Med. 2013, 368(5):407-415.
132. Mattila E., Uusitalo-Seppälä R., Wuorela M., et al. Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection. Gastroenterology 2012, 142(3):490-496.
133. Brandt L.J., Aroniadis O.C., Mellow M., et al. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am. J. Gastroenterol. 2012, 107(7):1079-1087.
134. Bakken J.S., Borody T., Brandt L.J., et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin. Gastroenterol. Hepatol. 2011, 9(12):1044-1049.
135. Kassam Z., Lee C.H., Yuan Y., et al. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am. J. Gastroenterol. 2013, 108(4):500-508.
136. Butler M.S., Blaskovich M.A., Cooper M.A. Antibiotics in the clinical pipeline in 2013. J.Antibiot. 2013, 66(10):571-591.
137. Musher D.M., Logan N., Hamill R.J., et al. Nitazoxanide for the treatment of Clostridium difficile colitis. Clin. Infect. Dis. 2006, 43(4):421-427.
138. Musher D.M., Logan N., Bressler A.M., et al. Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study. Clin. Infect. Dis. 2009, 48(4):e41-e46.
139. Musher D.M., Logan N., Mehendiratta V., et al. Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide. J.Antimicrob. Chemother. 2007, 59(4):705-710.
140. Baldoni D., Gutierrez M., Timmer W., et al. Cadazolid, a novel antibiotic with potent activity against Clostridium difficile: safety, tolerability and pharmacokinetics in healthy subjects following single and multiple oral doses. J.Antimicrob. Chemother. 2014, 69(3):706-714.
141. Locher H., Ritz D., Schroeder S., et al. Cadazolid, a novel quinolonyl-oxazolidinone antibiotic: mode of action and effect on Clostridium difficile toxin and spore formation. Poster (C1-1347) Presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2012.
142. Actelion. Cadazolid. Available from: (accessed 09.01.15). http://www1.actelion.com/en/scientists/development-pipeline/phase-3/cadazolid.page.
143. Citron D.M., Tyrrell K.L., Merriam C.V., et al. Invitro activities of CB-183,315, vancomycin, and metronidazole against 556 strains of Clostridium difficile, 445 other intestinal anaerobes, and 56 Enterobacteriaceae species. Antimicrob. Agents Chemother. 2012, 56(3):1613-1615.
144. Snydman D., Jacobus N., McDermott L. Activity of a novel cyclic lipopeptide, CB-183,315, against resistant Clostridium difficile and other Gram-positive aerobic and anaerobic intestinal pathogens. Antimicrob. Agents Chemother. 2012, 56(6):3448-3452.
145. Chesnel L., Sambol S., Gerding D. Treatment of CDAD with oral CB-183 315: time to recurrence, relapse and re-infection rates compared with vancomycin. Clin. Microbiol. Infect. 2012, 18(Suppl.3):380.
146. Herpers B.L., Vlaminckx B., Burkhardt O., et al. Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection. Clin. Infect. Dis. 2009, 48(12):1732-1735.
147. Lu C.-L., Liu C.-Y., Liao C.-H., et al. Severe and refractory Clostridium difficile infection successfully treated with tigecycline and metronidazole. Int. J. Antimicrob. Agents 2010, 35(3):311-312.
148. Food and Drug Administration. FDA Drug Safety Communication: Increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections. Available from: (accessed 21.06.14). http://www.fda.gov/Drugs/DrugSafety/ucm224370.htm.
149. Musgrave C.R., Bookstaver P.B., Sutton S.S., et al. Use of alternative or adjuvant pharmacologic treatment strategies in the prevention and treatment of Clostridium difficile infection. Int. J. Infect. Dis. 2011, 15(7):e438-e448.
150. Nelson R. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst. Rev. 2007, 3.
151. Fulco P., Wenzel R.P. Ramoplanin: a topical lipoglycodepsipeptide antibacterial agent. Expert Rev. Anti-infective Ther. 2006, 4(6):939-945.
152. Citron D.M., Tyrrell K.L., Merriam C.V., et al. Comparative invitro activities of LFF571 against Clostridium difficile and 630 other intestinal strains of aerobic and anaerobic bacteria. Antimicrob. Agents Chemother. 2012, 56(5):2493-2503.
153. Trzasko A., Leeds J.A., Praestgaard J., et al. Efficacy of LFF571 in a hamster model of Clostridium difficile infection. Antimicrob. Agents Chemother. 2012, 56(8):4459-4462.
154. Ting L.S., Praestgaard J., Grunenberg N., et al. Afirst-in-human, randomized, double-blind, placebo-controlled, single-and multiple-ascending oral dose study to assess the safety and tolerability of LFF571 in healthy volunteers. Antimicrob. Agents Chemother. 2012, 56(11):5946-5951.
155. Ritchie M.L., Romanuk T.N. Ameta-analysis of probiotic efficacy for gastrointestinal diseases. PLoS One 2012, 7(4):e34938.
156. D'Souza A.L., Rajkumar C., Cooke J., et al. Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. BMJ 2002, 324(7350):1361.
157. Lawrence S.J., Korzenik J.R., Mundy L.M. Probiotics for recurrent Clostridium difficile disease. J.Med. Microbiol. 2005, 54(9):905-906.
158. Pillai A., Nelson R. Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database Syst. Rev. 2008, 1(1).
159. Wullt M., Hagslätt M.-l.J., Odenholt I. Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial. Scand. J. Infect. Dis. 2003, 35(6-7):365-367.
160. ViroPharma Incorporated. Treatment with VP20621 (Non-Toxigenic Clostridium difficile: NTCD) in a Phase 2 Study Resulted in High Rates of Colonization and Statistically Significant Reductions in Recurrence of C.difficile Infection. Available from: (accessed 09.01.15). http://www.prnewswire.com/news-releases/treatment-with-vp20621-non-toxigenic-clostridium-difficile-ntcd-in-a-phase-2-study-resulted-in-high-rates-of-colonization-and-statistically-significant-reductions-in-recurrence-of-c-difficile-infection-204069451.html.
161. Sha S., Liang J., Chen M., et al. Systematic review: faecal microbiota transplantation therapy for digestive and nondigestive disorders in adults and children. Aliment. Pharmacol. Ther. 2014, 39(10):1003-1032.
162. Emanuelsson F., Claesson B.E., Ljungström L., et al. Faecal microbiota transplantation and bacteriotherapy for recurrent Clostridium difficile infection: a retrospective evaluation of 31 patients. Scand. J. Infect. Dis. 2014, 46(2):89-97. (2):89-97.
163. Tvede M., Rask-Madsen J. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet 1989, 333(8648):1156-1160.
164. Louie T., Cannon K., O'grady H., et al. Fecal microbiome transplantation (FMT) via oral fecal microbial capsules for recurrent Clostridium difficile infection (rCDI) (Abstract 89). IDWeek 2013, San Francisco, CA.
165. Youngster I., Russell G.H., Pindar C., et al. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. J.Am. Med. Assoc. 2014, 312(17):1772-1778.
166. Seres Health. Seres Health Presents Final Data for Study of SER-109 in Recurrent Clostridium difficile Infection at ICAAC 2014 Conference; Available from: (accessed 14.04.15). http://sereshealth.com/news/newsroom/seres_health_presents_final_data_for_study_of_ser-109_in_recurrent_clostridium_difficile_infection_at_icaac_2014_conference/.
167. Lowy I., Molrine D.C., Leav B.A., et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N.Engl. J. Med. 2010, 362(3):197.
168. Numan S.C., Veldkamp P., Kuijper E.J., et al. Clostridium difficile-associated diarrhoea: bovine anti-Clostridium difficile whey protein to help aid the prevention of relapses. Gut 2007, 56(6):888-889.
169. Mattila E., Anttila V.-J., Broas M., et al. Arandomized, double-blind study comparing Clostridium difficile immune whey and metronidazole for recurrent Clostridium difficile-associated diarrhoea: efficacy and safety data of a prematurely interrupted trial. Scand. J. Infect. Dis. 2008, 40(9):702-708.
170. Kotloff K.L., Wasserman S.S., Losonsky G.A., et al. Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults. Infect. Immun. 2001, 69(2):988-995.
171. Sougioultzis S., Kyne L., Drudy D., et al. Clostridium difficile toxoid vaccine in recurrent C.difficile-associated diarrhea. Gastroenterology 2005, 128(3):764-770.
172. Greenberg R.N., Marbury T.C., Foglia G., et al. Phase I dose finding studies of an adjuvanted Clostridium difficile toxoid vaccine. Vaccine 2012, 30(13):2245-2249.
173. Donald R.G., Flint M., Kalyan N., et al. Anovel approach to generate a recombinant toxoid vaccine against Clostridium difficile. Microbiology 2013, 159(Pt 7):1254-1266.
174. Tian J.-H., Fuhrmann S.R., Kluepfel-Stahl S., et al. Anovel fusion protein containing the receptor binding domains of C.difficile toxin A and toxin B elicits protective immunity against lethal toxin and spore challenge in preclinical efficacy models. Vaccine 2012, 30(28):4249-4258.
175. Tedesco F.J. Treatment of recurrent antibiotic-associated pseudomembranous colitis. Am. J. Gastroenterol. 1982, 77(4):220-221.
176. Weiss K. Toxin-binding treatment for Clostridium difficile: a review including reports of studies with tolevamer. Int. J. Antimicrob. Agents 2009, 33(1):4-7.
177. Surawicz C.M., McFarland L.V., Greenberg R.N., et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin. Infect. Dis. 2000, 31(4):1012-1017.
178. Dendukuri N., Costa V., McGregor M., et al. Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: a systematic review. Can. Med. Assoc. J. 2005, 173(2):167-170.
179. Wilson K.H., Sheagren J.N. Antagonism of toxigenic Clostridium difficile by nontoxigenic C.difficile. J.Infect. Dis. 1983, 147(4):733-736.
180. Villano S.A., Seiberling M., Tatarowicz W., et al. Evaluation of an oral suspension of VP20621, spores of nontoxigenic Clostridium difficile strain M3, in healthy subjects. Antimicrob. Agents Chemother. 2012, 56(10):5224-5229.
181. Petrof E.O., Khoruts A. From stool transplants to next-generation microbiota therapeutics. Gastroenterology 2014 May, 146(6):1573-1582.
182. Eiseman B., Silen W., Bascom G., et al. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 1958, 44(5):854-859.
183. You D.M., Franzos M.A., Holman R.P. Successful treatment of fulminant Clostridium difficile infection with fecal bacteriotherapy. Ann. Intern. Med. 2008, 148(8):632-633.
184. Trubiano J.A., Gardiner B., Kwong J.C., et al. Faecal microbiota transplantation for severe Clostridium difficile infection in the intensive care unit. Eur. J. Gastroenterol. Hepatol. 2013, 25(2):255-257.
185. Grehan M.J., Borody T.J., Leis S.M., et al. Durable alteration of the colonic microbiota by the administration of donor fecal flora. J.Clin. Gastroenterol. 2010, 44(8):551-561.
186. Buffie C.G., Bucci V., Stein R.R., et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 2015, 517(7533):205-208.
187. Kassam Z., Hundal R., Marshall J.K., et al. Fecal transplant via retention enema for refractory or recurrent Clostridium difficile infection. Arch. Intern. Med. 2012, 172(2):191-193.
188. Silverman M.S., Davis I., Pillai D.R. Success of self-administered home fecal transplantation for chronic Clostridium difficile infection. Clin. Gastroenterol. Hepatol. 2010, 8(5):471-473.
189. Gough E., Shaikh H., Manges A.R. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin. Infect. Dis. 2011, 53(10):994-1002.
190. Postigo R., Kim J. Colonoscopic versus nasogastric fecal transplantation for the treatment of Clostridium difficile infection: a review and pooled analysis. Infection 2012, 40(6):643-648.
191. Persky S.E., Brandt L.J. Treatment of recurrent Clostridium difficile-associated diarrhea by administration of donated stool directly through a colonoscope. Am. J. Gastroenterol. 2000, 95(11):3283-3285.
192. Hamilton M.J., Weingarden A.R., Sadowsky M.J., et al. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am. J. Gastroenterol. 2012, 107(5):761-767.
193. Ray A., Hardi R., Ramesh M., et al. Enema administration of RBX2660 (Microbiota suspension) for recurrent C.difficile infection: lessons learned from the PUNCH CD study. Am. Coll. Gastroenterol. 2014, 109:S192-S193.
194. Petrof E.O., Gloor G.B., Vanner S.J., et al. Stool substitute transplant therapy for the eradication of Clostridium difficile infection: 'RePOOPulating' the gut. Microbiome 2013, 1(1):1-12.
195. openbiome.org. (accessed 15.04.15).
196. Bakken J.S. Fecal bacteriotherapy for recurrent Clostridium difficile infection. Anaerobe 2009, 15(6):285-289.
197. Kassam Z., Lee C.H., Yuan Y., et al. Navigating long-term safety in fecal microbiota transplantation. Am. J. Gastroenterol. 2013, 108(108):1538.
198. Gens K.D., Elshaboury R.H., Holt J.S. Fecal microbiota transplantation and emerging treatments for Clostridium difficile infection. J.Pharm. Pract. 2013, 26(5):498-505.
199. Vrieze A., Van Nood E., Holleman F., et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012, 143(4):913-916. e7.
200. Friedman-Moraco R., Mehta A., Lyon G., et al. Fecal microbiota transplantation for refractory Clostridium difficile colitis in solid organ transplant recipients. Am. J. Transplant. 2014, 14(2):477-480.
201. Ihunnah C., Kelly C., Hohmann E., et al. Fecal microbiota transplantation (FMT) for treatment of Clostridium difficile infection (CDI) in immunocompromised patients (Abstract 10). American College of Gastroenterology (ACG) Annual Scientific Meeting 2013, California, San Diego.
202. U.S.Department of Health and Human Services (DHHS) and Food and Drug Administration (FDA) Guidance for Industry: Enforcement Policy Regarding Investigational New Drug Requirements for Use of Fecal Microbiota for Transplantation to Treat Clostridium difficile Infection Not Responsive to Standard Therapies April 30, 2014, Available from:. http://www.fda.gov/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/vaccines/ucm361379.htm.
203. Abougergi M.S., Kwon J.H. Intravenous immunoglobulin for the treatment of Clostridium difficile infection: a review. Dig. Dis. Sci. 2011, 56(1):19-26.
204. Abougergi M.S., Broor A., Cui W., et al. Intravenous immunoglobulin for the treatment of severe Clostridium difficile colitis: an observational study and review of the literature. J.Hosp. Med. 2010, 5(1):E1-E9.
205. O'Horo J., Safdar N. The role of immunoglobulin for the treatment of Clostridium difficile infection: a systematic review. Int. J. Infect. Dis. 2009, 13(6):663-667.
206. Muñoz P., Giannella M., Alcalá L., et al. Clostridium difficile-associated diarrhea in heart transplant recipients: is hypogammaglobulinemia the answer?. J.Heart Lung Transplant. 2007, 26(9):907-914.
207. Reichert J.M. Antibodies to watch in 2013: mid-year update. MAbs 2013.
208. Tjellström B., Stenhammar L., Eriksson S., et al. Oral immunoglobulin A supplement in treatment of Clostridium difficile enteritis. Lancet 1993, 341(8846):701-702.
209. Warny M., Fatimi A., Bostwick E., et al. Bovine immunoglobulin concentrate-Clostridium difficile retains C difficile toxin neutralising activity after passage through the human stomach and small intestine. Gut 1999, 44(2):212-217.
210. Leuzzi R., Adamo R., Scarselli M. Vaccines against Clostridium difficile. Hum. Vaccines Immunother. 2014, 10(6):0-1.
211. Foglia G., Shah S., Luxemburger C., et al. Clostridium difficile: development of a novel candidate vaccine. Vaccine 2012, 30(29):4307-4309.
212. Permpoonpattana P., Hong H.A., Phetcharaburanin J., et al. Immunization with Bacillus spores expressing toxin A peptide repeats protects against infection with Clostridium difficile strains producing toxins A and B. Infect. Immun. 2011, 79(6):2295-2302.
213. Kreutzer E., Milligan F. Treatment of antibiotic-associated pseudomembranous colitis with cholestyramine resin. Johns Hopkins Med. J. 1978, 143(3):67-72.
214. Taylor N.S., Bartlett J.G. Binding of Clostridium difficile cytotoxin and vancomycin by anion-exchange resins. J.Infect. Dis. 1980, 141(1):92-97.
215. Kelly C.P., Becker S., Linevsky J.K., et al. Neutrophil recruitment in Clostridium difficile toxin A enteritis in the rabbit. J.Clin. Invest. 1994, 93(3):1257-1265.
216. Kelly C.P., Kyne L. The host immune response to Clostridium difficile. J.Med. Microbiol. 2011, 60(Pt 8):1070-1079.
217. Linevsky J.K., Pothoulakis C., Keates S., et al. IL-8 release and neutrophil activation by Clostridium difficile toxin-exposed human monocytes. Am. J. Physiol. 1997, 273(6 Pt 1):G1333-G1340.
218. Warny M., Keates A.C., Keates S., et al. p38 MAP kinase activation by Clostridium difficile toxin A mediates monocyte necrosis, IL-8 production, and enteritis. J.Clin. Invest. 2000, 105(8):1147-1156.
219. Li Y., Figler R.A., Kolling G., et al. Adenosine A2A receptor activation reduces recurrence and mortality from Clostridium difficile infection in mice following vancomycin treatment. BMC Infect. Dis. 2012, 12(1):342.
220. Kang J.K., Hwang J.S., Nam H.J., et al. The insect peptide coprisin prevents Clostridium difficile-mediated acute inflammation and mucosal damage through selective antimicrobial activity. Antimicrob. Agents Chemother. 2011, 55(10):4850-4857.
221. Hing T.C., Ho S., Shih D.Q., et al. The antimicrobial peptide cathelicidin modulates Clostridium difficile-associated colitis and toxin A-mediated enteritis in mice. Gut 2013, 62(9):1295-1305.
222. Koon H.W., Ho S., Hing T.C., et al. Fidaxomicin inhibits Clostridium difficile toxin A-mediated enteritis in mouse ileum. Antimicrob. Agents Chemother. 2014 Aug, 58(8):4642-4650. AAC. 02783-14.